clinical

Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025

Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025

Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta Cell Function for People with…

13 hours ago
Axtria Launches LUCCID to Transform Clinical Data Management with GenAIAxtria Launches LUCCID to Transform Clinical Data Management with GenAI

Axtria Launches LUCCID to Transform Clinical Data Management with GenAI

Delivers Technology for Automating Unstructured Clinical Data Extraction with Over 90% Accuracy BERKELEY HEIGHTS, N.J., April 29, 2025 /PRNewswire/ --…

4 days ago
BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia, Type 47 (SPG47)BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia, Type 47 (SPG47)

BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia, Type 47 (SPG47)

April 28, 2025 04:00 ET  | Source: BlackfinBio CHESHIRE, United Kingdom, April 28, 2025 (GLOBE NEWSWIRE) -- BlackfinBio Ltd, a…

6 days ago
Three-Year Data of Zenflows Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPHThree-Year Data of Zenflows Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH

Three-Year Data of Zenflows Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH

SOUTH SAN FRANCISCO, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc. announced today the results of long-term data demonstrating…

6 days ago
Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical ReadoutsCytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts

Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts

April 23, 2025 03:00 ET  | Source: Cytovation New funds provided largely by existing investors, led by Sandwater  Phase 2…

2 weeks ago
Antag Therapeutics expands senior team to support clinical progressAntag Therapeutics expands senior team to support clinical progress

Antag Therapeutics expands senior team to support clinical progress

Copenhagen, Denmark, 23 April 2025 – Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity,…

2 weeks ago
Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic RetinopathyVantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

LONDON, April 11, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye…

3 weeks ago
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease

HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing…

4 weeks ago
George Clinical Rebrands as Emerald Clinical Trials

George Clinical Rebrands as Emerald Clinical Trials

New name reflects company's growth and vision to help bring certainty and transparency to global clinical trials SINGAPORE, April 7,…

4 weeks ago
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from…

1 month ago